Abstract
We present a practical synthesis of both enantiomers of 1,2,3,4-tetrahydroisoquinoline derivative IPPAM-1 (1), which is a positive allosteric modulator (PAM) of prostacyclin receptor (IP) and a candidate for treatment of pulmonary arterial hypertension without the side effects caused by IP agonists. Assay of cAMP production by CHO-K1 cells stably expressing human IP clearly demonstrated that the IPPAM activity resides exclusively on the R-form of 1.
Keywords:
Positive allosteric modulator; Prostacyclin; Prostacyclin receptor; Pulmonary arterial hypertension; Tetrazole derivative.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Allosteric Regulation
-
Animals
-
Antihypertensive Agents / chemical synthesis
-
Antihypertensive Agents / chemistry*
-
Antihypertensive Agents / therapeutic use
-
CHO Cells
-
Cricetinae
-
Cricetulus
-
Cyclic AMP / metabolism
-
Humans
-
Hypertension, Pulmonary / drug therapy
-
Receptors, Epoprostenol / agonists
-
Receptors, Epoprostenol / genetics
-
Receptors, Epoprostenol / metabolism*
-
Stereoisomerism
-
Tetrahydroisoquinolines / chemical synthesis
-
Tetrahydroisoquinolines / chemistry*
-
Tetrahydroisoquinolines / therapeutic use
Substances
-
Antihypertensive Agents
-
Receptors, Epoprostenol
-
Tetrahydroisoquinolines
-
Cyclic AMP